Amgen, a biopharmaceutical company based in Thousand Oaks, Calif., and Syapse, a precision medicine startup headquartered in San Francisco, announced a partnership on May 2 that will use precision medicine techniques to develop cancer treatments.
Together, the two companies will spearhead a research analytics solution, using the existing Syapse Learning Health Network, that will identify cancer patients whose most effective treatments have yet to be developed. Those patients will be matched with Amgen-sponsored clinical trials, which will be brought to community health system sites to increase accessibility. Amgen will also use the Syapse data to further the development of various cancer therapies.
Additionally, the project will allow physicians and researchers to access analytics and evidence-based insights within the Learning Health Network and discover opportunities for collaborative research, as part of Syapse and Amgen's goal of increasing worldwide access to cancer treatment regardless of income or location.
More articles about health IT:
How CHI's virtually integrated care model seeks to transform nursing
NPR kicks off series on tech changing the human experience
Senate health chair: Let's not repeat 'terrifying' meaningful use rollout